Arterial Hypertension-clinical Trials Update 2023

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 13

PMID 37443261

Authors

Felix Gotzinger

Michael Kunz

Lucas Lauder

Michael Bohm

Felix Mahfoud

Affiliations

Soon will be listed here.

Abstract

Arterial hypertension is associated with increased morbidity and mortality and research in the field is highly dynamic. This summary reviews the most important clinical trials published in 2022 and early 2023. Findings on new pharmacological approaches to treat resistant hypertension are presented and new knowledge about the optimal timing of the antihypertensive medication intake is discussed. It is focused on optimal blood pressure treatment targets and the problem of treatment and guideline inertia is acknowledged. Information about pregnancy-related hypertension is presented and blood pressure control following percutaneous thrombectomy after ischemic stroke is discussed. Finally, novel clinical data on device-based approaches to treat hypertension are summarized. The hypertension trials update summarizes the most important clincal trials on hypertension research in 2022 and early 2023. CTD - chlorthalidone, CV - cardiovascular, HCT - hydrochlorothiazide, SBP - systolic blood pressure, RDN - renal denervation *depicts systolic blood pressure only.

Citing Articles

Association of monocyte-lymphocyte ratio and myocardial infarction in the U.S. population with diabetes.

Wu Y, Xiang H, Yuan M Front Cardiovasc Med. 2024; 11:1432838.

PMID: 39403591 PMC: 11472363. DOI: 10.3389/fcvm.2024.1432838.

Research status and frontiers of renal denervation for hypertension: a bibliometric analysis from 2004 to 2023.

Li J, Zhang X, Jiang Y, Wang H, Gao X, Hu Y J Health Popul Nutr. 2024; 43(1):142.

PMID: 39252135 PMC: 11385481. DOI: 10.1186/s41043-024-00626-z.

Effects of cocoa consumption on cardiometabolic risk markers: Protocol for a systematic review and meta-analysis of randomized controlled trials.

Arisi T, da Silva D, Stein E, Weschenfelder C, de Oliveira P, Marcadenti A PLoS One. 2024; 19(9):e0309824.

PMID: 39250491 PMC: 11383207. DOI: 10.1371/journal.pone.0309824.

Risk factors and prevalence of hypertension in older adults from south-eastern Poland: an observational study.

Leszczak J, Czenczek-Lewandowska E, Asif M, Baran J, Mazur A, Wyszynska J Sci Rep. 2024; 14(1):1450.

PMID: 38228769 PMC: 10792009. DOI: 10.1038/s41598-024-52009-3.

References

Forouzanfar M, Liu P, Roth G, Ng M, Biryukov S, Marczak L . Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017; 317(2):165-182. DOI: 10.1001/jama.2016.19043. View

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339. View

Carey R, Sakhuja S, Calhoun D, Whelton P, Muntner P . Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2018; 73(2):424-431. PMC: 6693520. DOI: 10.1161/HYPERTENSIONAHA.118.12191. View

Daugherty S, Powers J, Magid D, Tavel H, Masoudi F, Margolis K . Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13):1635-42. PMC: 3343635. DOI: 10.1161/CIRCULATIONAHA.111.068064. View

Myat A, Redwood S, Qureshi A, Spertus J, Williams B . Resistant hypertension. BMJ. 2012; 345:e7473. DOI: 10.1136/bmj.e7473. View

Williams B . Resistant hypertension: an unmet treatment need. Lancet. 2009; 374(9699):1396-8. DOI: 10.1016/S0140-6736(09)61600-7. View

Sarafidis P, Bakris G . Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52(22):1749-57. DOI: 10.1016/j.jacc.2008.08.036. View

Whelton P, Carey R, Aronow W, Casey Jr D, Collins K, Himmelfarb C . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on.... J Am Coll Cardiol. 2017; 71(19):e127-e248. DOI: 10.1016/j.jacc.2017.11.006. View

Gotzinger F, Kunz M, Lauder L, Bohm M, Mahfoud F . Arterial hypertension - clinical trials update 2022. Hypertens Res. 2022; 45(7):1140-1146. DOI: 10.1038/s41440-022-00931-2. View

10.

Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Bohm M . Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376(9756):1903-9. DOI: 10.1016/S0140-6736(10)62039-9. View

11.

Bhatt D, Vaduganathan M, Kandzari D, Leon M, Rocha-Singh K, Townsend R . Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022; 400(10361):1405-1416. DOI: 10.1016/S0140-6736(22)01787-1. View

12.

Esler M, Bohm M, Sievert H, Rump C, Schmieder R, Krum H . Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014; 35(26):1752-9. PMC: 5994826. DOI: 10.1093/eurheartj/ehu209. View

13.

Freeman M, Bond M, Murphy B, Hui J, Isaacsohn J . Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2022; 46(1):108-118. PMC: 9747611. DOI: 10.1038/s41440-022-01070-4. View

14.

Freeman M, Halvorsen Y, Marshall W, Pater M, Isaacsohn J, Pearce C . Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2022; 388(5):395-405. DOI: 10.1056/NEJMoa2213169. View

15.

Fagard R, Thijs L, Staessen J, Clement D, De Buyzere M, De Bacquer D . Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009; 23(10):645-53. DOI: 10.1038/jhh.2009.9. View

16.

Kario K . Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010; 56(5):765-73. DOI: 10.1161/HYPERTENSIONAHA.110.157149. View

17.

Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T . Nighttime hemodynamic phenotype. A novel risk factor for cardiovascular disease, especially heart failure: the practitioner-based nationwide JAMP study. Clin Res Cardiol. 2022; 112(1):98-110. DOI: 10.1007/s00392-022-02051-w. View

18.

Hermida R, Calvo C, Ayala D, Fernandez J, Covelo M, Mojon A . Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005; 23(10):1913-22. DOI: 10.1097/01.hjh.0000182522.21569.c5. View

19.

Ho C, Chowdhury E, Doust J, Nelson M, Reid C . The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review. J Hum Hypertens. 2021; 35(4):308-314. DOI: 10.1038/s41371-020-00469-1. View

20.

Mackenzie I, Rogers A, Poulter N, Williams B, Brown M, Webb D . Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022; 400(10361):1417-1425. PMC: 9631239. DOI: 10.1016/S0140-6736(22)01786-X. View